文献速递间质性肺疾病

人工智能在特发性肺纤维化中的应用:进展、挑战与未来方向

Artificial intelligence in idiopathic pulmonary fibrosis: advances, challenges and future directions.
PubMed 文献 · Eur Respir J · 2026-01-22

本文综述人工智能(尤其是机器学习和深度学习)在特发性肺纤维化(IPF)管理中的应用进展。卷积神经网络可提升高分辨率CT分析准确性以助早期诊断,预测模型利用临床、形态、转录和影像数据评估进展与风险分层,AI驱动药物发现已发现具抗纤维化作用的NCK相互作用激酶抑制剂。但数据异质性、模型可解释性及大规模多中心验证需求阻碍临床整合。

要点

  • 深度学习卷积神经网络可提升HRCT分析准确性,辅助IPF早期精准诊断。
  • 基于临床、影像、转录等多模态数据的ML/DL模型可用于评估疾病进展和风险分层。
  • AI驱动药物发现已识别具强抗纤维化作用的NCK相互作用激酶抑制剂。

核心结论

  • 人工智能在IPF诊断、预后评估和治疗策略优化方面展现潜力,但数据异质性、模型可解释性和大规模多中心验证需求阻碍其广泛临床整合。

研究设计与样本

  • 综述类文章,检索范围未在摘要中明确报告。

主要发现

  • 卷积神经网络作为深度学习的一部分,可提升高分辨率计算机断层扫描(HRCT)分析准确性,促进IPF早期精准诊断。
  • 预测性机器学习和深度学习模型利用临床、形态学、转录和影像数据评估疾病进展并按风险对患者分层,改善预后评估。
  • AI驱动药物发现通过识别新治疗靶点优化治疗策略,近期已发现具强抗纤维化特性的NCK相互作用激酶抑制剂。
  • 数据异质性、模型可解释性及需大规模多中心研究稳健验证是阻碍AI临床整合的主要挑战。

临床怎么用

  • 临床可关注AI辅助HRCT分析用于IPF早期诊断和精准评估。
  • 可利用多模态数据驱动的预测模型辅助疾病进展评估和风险分层。
  • AI驱动药物发现为IPF靶向治疗提供新方向,但临床落地需等待验证。

局限性

  • 数据异质性影响模型泛化能力。
  • 模型可解释性不足限制临床信任和推广。
  • 缺乏大规模多中心研究的稳健验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Idiopathic pulmonary fibrosis (IPF) is a progressive disease of unknown aetiology, characterised by a radiological and/or morphological pattern of usual interstitial pneumonia. Its diagnosis is challenging, and disease progression is often variable and unpredictable. In recent years the introduction of artificial intelligence (AI), particularly machine learning (ML) and deep learning (DL) models, has shown the potential to improve the diagnosis, prognosis and therapeutic strategies for IPF. As part of DL, convolutional neural networks enhance the accuracy of high-resolution computed tomography analysis, facilitating early and precise diagnosis. Likewise, predictive ML and DL models are being developed using clinical, morphological, transcriptional and imaging data to assess disease progression and stratify patients by risk, thereby improving prognosis evaluation. Furthermore, AI-driven drug discovery may optimise treatment strategies by identifying novel therapeutic targets, as recently demonstrated with the discovery of an NCK-interacting kinase inhibitor with strong antifibrotic properties. However, several challenges hamper widespread clinical integration and real-life implementation, including data heterogeneity, model interpretability and the need for robust validation through large-scale, multicentre studies. Future research should prioritise the development of standardised models of AI in large cohorts of IPF patients, combining clinical, imaging, morphological, multi-omics and other data, and enhance model transparency to strengthen clinical confidence. With continued advancements, AI holds potential to improve IPF management, enabling early diagnosis, individualised prognosis and targeted therapy, all aimed at improving patient outcomes. In this review, we explore the evolving role of AI in IPF management, its potential to support clinical decisions and the challenges to its clinical integration.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Selman M, Buendia-Roldan I, Pardo A, et al. Artificial intelligence in idiopathic pulmonary fibrosis: advances, challenges and future directions. Eur Respir J. 2026. PMID: 41381227. doi:10.1183/13993003.01112-2025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。